Contraindicated in:
Use Cautiously in:
CNS: malaise, dizziness.
CV: hypertension, hypotension.
GI: anorexia, mucositis, nausea, vomiting, abdominal pain, constipation, diarrhea, taste alteration.
Derm: STEVENS-JOHNSON SYNDROME, alopecia, pruritis, rash, urticaria.
Endo: sterility.
Hemat: ANEMIA, leukopenia, THROMBOCYTOPENIA.
Local: phlebitis at IV site.
Misc: ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS, fever.
Drug-Drug:
Testicular Neoplasms
Small-Cell Carcinoma of the Lung
Therapeutic Classification: antineoplastics
Pharmacologic Classification: podophyllotoxin derivatives
Absorption: After IV administration, etoposide phosphate is rapidly converted to etoposide.
Distribution: Rapidly distributed; poorly enters the CSF; probably crosses placenta; enters breast milk.
Protein Binding: 97%.
Metabolism/Excretion: Some metabolism by the liver with biliary excretion, 44% excreted in feces; 45% excreted unchanged by the kidneys.
Half-life: 4–11 hr.
(noted as effects on blood counts)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| IV | unknown | 12–19 days (granulocytes) 10–15 days (platelets) | 21 days |
NDC Code*